BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 07, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ASP2408: Phase I started

The companies' Perseid Therapeutics LLC JV began a double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial to evaluate single ascending-doses of IV ASP2408 in 65 healthy volunteers. The trial start triggered...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >